Cheng Tingting, Tai Zongguang, Shen Min, Li Ying, Yu Junxia, Wang Jiandong, Zhu Quangang, Chen Zhongjian
School of Pharmacy, Bengbu Medical College, 2600 Donghai Road, Bengbu 233030, China.
Shanghai Skin Disease Hospital, School of Medicine, Tongji University, 1278 Baode Road, Shanghai 200443, China.
Pharmaceutics. 2023 Aug 21;15(8):2165. doi: 10.3390/pharmaceutics15082165.
Skin diseases are among the most prevalent non-fatal conditions worldwide. The transdermal drug delivery system (TDDS) has emerged as a promising approach for treating skin diseases, owing to its numerous advantages such as high bioavailability, low systemic toxicity, and improved patient compliance. However, the effectiveness of the TDDS is hindered by several factors, including the barrier properties of the stratum corneum, the nature of the drug and carrier, and delivery conditions. In this paper, we provide an overview of the development of the TDDS from first-generation to fourth-generation systems, highlighting the characteristics of each carrier in terms of mechanism composition, penetration method, mechanism of action, and recent preclinical studies. We further investigated the significant challenges encountered in the development of the TDDS and the crucial significance of clinical trials.
皮肤疾病是全球最普遍的非致命性疾病之一。经皮给药系统(TDDS)由于具有高生物利用度、低全身毒性和提高患者依从性等诸多优点,已成为治疗皮肤疾病的一种有前景的方法。然而,TDDS的有效性受到多种因素的阻碍,包括角质层的屏障特性、药物和载体的性质以及给药条件。在本文中,我们概述了TDDS从第一代到第四代系统的发展历程,重点介绍了每种载体在作用机制、组成、渗透方法、作用机制以及近期临床前研究方面的特点。我们还进一步研究了TDDS开发过程中遇到的重大挑战以及临床试验的关键意义。